H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Capricor Therapeutics (CAPR) to $24 from $77 and keeps a Buy rating on the shares after the company received a complete response letter from the FDA for deramiocel, its cell therapy candidate for the treatment of cardiomyopathy in Duchenne muscular dystrophy patients. The firm does not see the CRL “as the end of the story.” The FDA offered Capricor the opportunity to request a Type A meeting, and H.C. Wainwright’s positive thesis on deramiocel being approved for DMD cardiomyopathy following resubmission remains unchanged, the analyst tells investors in a research note. The firm pushed out the approval year for deramiocel to 2026 from 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics’ Deramiocel: Overcoming Setbacks with Promising Phase 3 Trial and Long-term Efficacy Data
- Capricor Therapeutics Stock (CAPR) Plummets 40% on FDA Rejection
- Morning Movers: Capricor Therapeutics plunges following CRL from FDA
- Video: Capricor plunges after CRL, Performance Foods up after seeing interest
- Capricor Receives FDA CRL for Deramiocel BLA